The QualityStocks Daily Friday, November 18th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(AITX) $0.0110 +48.65%

The Stock Dork(PXMD) $2.1300 +37.42%

Schaeffer's(ISEE) $21.6500 +25.58%

The QualityStocks Daily Stock List

Artificial Intelligence Technology Solutions (AITX)

QualityStocks, The Street Report, Investors Alley and InvestorPlace reported earlier on Artificial Intelligence Technology Solutions (AITX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Artificial Intelligence Technology Solutions Inc. (OTC: AITX) is focused on delivering robotic and artificial intelligence solutions for monitoring, security and operational needs. The company’s AI technologies are supported by custom cloud and software services and paired with multi-use hardware, which helps to intelligently integrate and automate operational, concierge and security tasks.

The firm has its headquarters in Reno, Nevada and was founded by John B. Crawford in 2010, on March 25. Before changing its name in August 2018 to Artificial Intelligence Technology Solutions Inc., the firm was known as On The Move Systems Corp. The company serves consumers in the U.S. and in particular, automobile fleet administrators and vehicle dealerships.

The company operates through its wholly-owned subsidiaries, one of which is Robotic Assistance Devices Inc. The subsidiary develops unique technology, specifically; mobileware, cloudware, software and hardware, which are used in the development of powerful tools like RADGuard, RADPMC and RADSOC as well as to improve performance in companies.

The firm is also engaged in the provision of mobile electronic services and offers after-market video, audio and electronic upgrades for boats, recreational vehicles and automobiles.

The company recently entered into an agreement with EAGL Technology Inc. for the provision of the latter firm’s gunshot detection system in all present and future RAD devices. The integration of EAGL solutions into the innovative products will not only make the products more popular but also expand their reach into the markets they serve, which will be good for investments as well as the firm’s stock.

Artificial Intelligence Technology Solutions (AITX), closed Friday's trading session at $0.011, up 48.6486%, on 78,116,967 volume. The average volume for the last 3 months is 1.349M and the stock's 52-week low/high is $0.006/$0.0335.

ConforMIS (CFMS)

StockMarketWatch, StreetInsider, MarketBeat, The Street, QualityStocks, Marketbeat.com, PoliticsAndMyPortfolio, Trades Of The Day, TopPennyStockMovers, BUYINS.NET, Zacks, InvestorPlace, HotOTC, Hit and Run Candle Sticks, Buzz Stocks, PennyStockScholar, Daily Trade Alert, Mega Stock Alerts, OTCtipReporter, Barchart, PennyStockProphet, Profitable Trader Authority, Rick Saddler, Schaeffer's, StockOnion and Penny Pick Finders reported earlier on ConforMIS (CFMS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ConforMIS Inc. (NASDAQ: CFMS) (FRA: 308) is a medical technology firm that develops, manufactures and sells various joint replacement implants as well as personalized tibia and femoral knee implants for joint damages and the treatment of osteoarthritis.

The firm, which is based in Billerica, Massachusetts, was founded in 2004. ConforMIS markets and sells its services and products to medical facilities and hospitals using independent sales representatives, sales force and distributors located in the U.S., Australia, Germany, Spain, the United Kingdom, Hungary, Austria, Monaco, Ireland, Malaysia, Switzerland, Hong Kong and Singapore.

ConforMIS uses its iFit image-to-implant platform to create individually shaped and sized implants that fit each patient’s anatomy. This is in addition to offering customized implants that have been specifically designed to restore the natural shape of an individual’s knee.

ConforMIS products include iTotal PS, a substituting posterior cruciate ligament, iTotal CR; which is a total knee replacement implant, iUni, a uni-compartmental personalized knee replacement product to treat the lateral or medial compartment of a patient’s knee and iDuo, a bi-compartmental personalized knee replacement system. The company also provides a hip replacement product known as Conformis Hip System.

As of 2021, the firm had won FDA approval for its iTotal CR and iTotal PS systems. Data has shown that roughly a million people in the U.S. undergo joint replacement surgery every year and with these minimally traumatic implant solutions out there in the market, demand is bound to surge, significantly. This will be good for ConforMIS’ growth and stocks.

ConforMIS (CFMS), closed Friday's trading session at $2.03, up 28.481%, on 1,348,729 volume. The average volume for the last 3 months is 4.333M and the stock's 52-week low/high is $1.20/$25.50.

Brookdale Senior Living (BKD)

InvestorPlace, StreetInsider, MarketBeat, MarketClub Analysis, SmarTrend Newsletters, Marketbeat.com, Zacks, Barchart, StocksEarning, INO.com Market Report, Daily Trade Alert, The Online Investor, The Street, NasdaqReport, Wealth Insider Alert, Schaeffer's, StockMarketWatch, TradingMarkets, ChartAdvisor, Daily Wealth, Forbes, BUYINS.NET, Insider Wealth Alert, Daily Market Beat, Kiplinger Today, Louis Navellier, Market Intelligence Center Alert, The Best Newsletters, AllPennyStocks, Trades Of The Day, PennyOmega, SmallCapInvestor, Street Insider, StreetAuthority Daily and Market Intelligence Center reported earlier on Brookdale Senior Living (BKD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Brookdale Senior Living, Inc. (NYSE: BKD) (FRA: B7S) is a firm that is focused on owning, managing and operating senior living communities.

The firm has its headquarters in Brentwood, Tennessee and was incorporated in 1978. It operates as part of the medical facilities industry, under the healthcare sector. The firm serves consumers in the United States.

The company operates through the Assisted Living and Memory Care, Independent Living and Continuing Care Retirement Communities (CCRCs) segments. The Assisted Living and Memory Care segment owns or leases communities comprising of freestanding single-story communities and freestanding multi-story communities, which provide housing and 24-hour assistance with activities of daily living for the company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. On the other hand, the CCRCs segment owns or leases communities that offer a range of living arrangements, including independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. As of December 2021, the enterprise owned 347 communities, leased 299 communities, and managed 33 communities on behalf of others.

The company, whose latest financial results show increases in its revenues, remains committed to growing and enriching the lives of its patients as well as providing residents with opportunities to improve wellness and stay connected with their loved ones.

Brookdale Senior Living (BKD), closed Friday's trading session at $3.14, up 0.96463%, on 4,332,721 volume. The average volume for the last 3 months is 284 and the stock's 52-week low/high is $2.88/$7.605.

De Grey Mining (DGMLF)

We reported earlier on De Grey Mining (DGMLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

De Grey Mining Limited (OTC: DGMLF) (ASX: DEG) (FRA: DGD) is a gold explorer and project development firm that is focused on exploring mineral properties, with a focus on base and precious metals like gold, silver, zinc and platinum.

The firm has its headquarters in West Perth, Australia and was incorporated in 2000 by Michael J. Baker and Denis William O’Mearais. It operates as part of the gold industry, under the basic materials sector. The firm serves consumers around the globe.

Geographically, the enterprise only operates in Australasia. Its primary focus lies in the Pilbara region on the Mallina Gold Project, which has been found to be prospective for gold mineralization. It holds 100% interest in this project, which covers an area of approximately 1,500 km2 and is located in Western Australia. The project’s area is centered around the Hemi deposit, which is situated within 10 km of two sealed highways, approximately 5 km from a gas pipeline. Its tenement package is prospective for gold, other precious metals and also comprises significant base metals resources (Zn-Ag-Pb) as well as lithium prospects. Hemi is made up of a series of zones: Aquila, Brolga, Crow and Falcon. Gold mineralization at Hemi is hosted in a series of intrusions associated with stringer and disseminated sulfide-rich zones. It also holds discovery targets in the Greater Hemi Region, located within a 15 km radius of Hemi, which includes four intrusion targets: Scooby, Antwerp, Shaggy and Alectroenas.

The company remains focused on advancing its exploration activities and increasing gold production, which will generate additional revenues for the company and help create value for its shareholders.

De Grey Mining (DGMLF), closed Friday's trading session at $0.8453, up 3.756%, on 284 volume. The average volume for the last 3 months is 100 and the stock's 52-week low/high is $0.49995/$1.07.

Ceconomy AG (MTAGF)

We reported earlier on Ceconomy AG (MTAGF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ceconomy AG (OTC: MTAGF) (FRA: CEC) (ETR: CEC) is a company involved in the consumer electronics retail business.

The firm has its headquarters in Dusseldorf, Germany and was incorporated in 1996. It operates as part of the specialty retail industry, under the consumer cyclical sector. The firm serves consumers in Europe.

The company operates in an attractive market fuelled by innovation and increasing demand for solutions. It operates in the DACH (Germany, Austria, Switzerland, Hungary), Western and Southern Europe, Eastern Europe geographical segments.

The enterprise operates approximately 850 stores in fourteen countries under the MediaMarkt brand; and approximately 170 stores in three countries under the Saturn brand. Its other brands include Deutsche Technikberatung, RMG and JUKE! Under the Saturn and MediaMarkt brand names, it operates retail chains selling television sets, personal computers and tablets, consoles and computer games, smartphones, music players, household appliances, small kitchen appliances, outdoor equipment, drones and navigation devices, among others. Deutsche Technikberatung offers professional assistance with installing, connecting and troubleshooting electronic devices. Retail Media Group (RMG) develops customized online advertising campaigns on the basis of anonymous visitor and purchasing data. Under the JUKE! brand name, the enterprise operates a digital platform which publishes songs, films, games and e-books. It also operates Flip4New for selling used electronic articles online.

The firm has the right platform to expand into new income pools and accelerate its growth path. This will help generate additional revenues for the firm while also bolstering its overall growth, which will help create value for its shareholders.

Ceconomy AG (MTAGF), closed Friday's trading session at $2.16, even for the day, on 100 volume. The average volume for the last 3 months is 10 and the stock's 52-week low/high is $2.10/$4.223.

Mandarin Oriental International (MAORF)

We reported earlier on Mandarin Oriental International (MAORF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Mandarin Oriental International Limited (OTC: MAORF) (FRA: 1C4) (LON: MDO) (SGX: M04) is a global hotel investment and management firm that is focused on owning and operating hotels, resorts and residences.

The firm has its headquarters in Quarry Bay, Hong Kong and was incorporated in 1986, on December 9th. It operates as part of the lodging industry, under the consumer cyclical sector. The firm serves consumers in the Americas, Africa, the Middle East, Europe and Asia.

The company operates through the Hotel Ownership, Hotel and Residences Branding and Management, and Property Development segment. Its subsidiaries include Mandarin Oriental Tokyo KK, Mandarin Oriental Hotel Group Limited, P.T. Jaya Mandarin Agung, Mandarin Oriental Hyde Park Limited, MOHG Hotel (Paris) Sarl and Portals Hotel Site LLC, among others.

The enterprise has deluxe and first class hotels, resorts and residences around the world. It operates or has under development forty-four hotels representing almost 11,000 rooms in 24 countries, with 10 hotels in the Americas, 20 hotels in Asia and 14 in Europe, Middle East and North Africa. In addition, it operates, or has under development 15 residences at Mandarin Oriental connected to its properties. Mandarin Oriental Hotel Group International Limited, which operates from Hong Kong, manages the activities of the company's hotels. The enterprise operates 36 hotels and seven residences in 24 countries and territories. It is also involved in the hotel and residences branding and management; and property development activities.

The company, which is focused on revenue growth and meeting its consumer demands, has grown its revenue by 118% over the past year. It is committed to better meeting consumer needs and growing, which will help create shareholder value.

Mandarin Oriental International (MAORF), closed Friday's trading session at $1.75, even for the day. The average volume for the last 3 months is 200 and the stock's 52-week low/high is $1.56/$2.32.

Trainline PLC (TNLIF)

MarketBeat, Trades Of The Day and Daily Trade Alert reported earlier on Trainline PLC (TNLIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Trainline PLC (OTC: TNLIF) (LON: TRN) (FRA: 2T9A) (BMV: TRNEN) is an independent rail and coach travel platform which sells rail and coach tickets globally.

The firm has its headquarters in London, the United Kingdom and was incorporated in 1997. It operates as part of the travel services industry, under the consumer cyclical sector. The firm serves consumers around the globe.

The company is a one-stop shop for rail and coach travel bringing together millions of routes, fares and journey times from 220 rail and coach carriers across 45 countries. It sells rail and coach tickets to millions of travelers globally, allowing them to seamlessly search, book and manage their journeys all in one place through its website and mobile app.

The enterprise operates through the UK Trainline Partner Solutions, UK Consumer and International segments. The UK Trainline Partner Solutions segment provides travel portal platforms for corporates and travel management firms and white label e-commerce platforms for train operating companies within the UK. The UK Consumer segment offers travel apps and websites for individual travelers for journeys in the UK. On the other hand, the International segment offers travel apps and websites for individual travelers for journeys outside the UK. It provides routes, fares, and journey times from 270 rail and coach carriers across forty-five countries.

The firm recently gave an operations update, with its CEO noting that more individuals were recognizing that travelling by train was better for the environment and that the appetite to do so would increase. An increase in demand will generate additional revenues for the firm.

Trainline PLC (TNLIF), closed Friday's trading session at $3.4, even for the day. The average volume for the last 3 months is 9.529M and the stock's 52-week low/high is $3.34/$4.32.

Nikola Corporation (NKLA)

Green Car Stocks, InvestorPlace, Schaeffer's, MarketClub Analysis, StocksEarning, The Street, QualityStocks, MarketBeat, Kiplinger Today, Trades Of The Day, StreetInsider, Daily Trade Alert, The Online Investor, Zacks, Early Bird, Cabot Wealth, Louis Navellier, Wealth Insider Alert, CNBC Breaking News, MarketTamer, Outsider Club, StockMarketWatch, Daily Profit and Investopedia reported earlier on Nikola Corporation (NKLA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The market for electric vehicles is booming; however, the shortage of battery-related materials such as lithium, nickel and cobalt could jeopardize the adoption of these vehicles. If this issue persists, factories may close and automakers may face financial penalties for failing to meet emission standards.

The rising EV battery demand is expected to necessitate 50 new lithium projects, 60 nickel mines, and 17 cobalt developments as we approach 2030, according to the International Energy Agency. This poses a serious danger for a mining sector that takes a long period of time (15 years in some cases) to come up with a project. Because of this, car makers have resolved to forego conventional supply networks and head straight to the mines for the needed raw materials.

Mercedes-Benz is among the EV manufacturing companies that have entered into arrangement deals with miners, by signing a purchase product assurance that aids the miners in obtaining financing. “This is a very unique occurrence that seemed unthinkable five years back,” said Ola Källenius.

According to Mercedes-Benz, the capacity to obtain these minerals will determine how long car manufacturers will survive in the sector. As a result, the car makers are traveling all the way down the supply chain to the actual miners in an effort to obtain the minerals at a lower cost while still ensuring that ethical and emissions standards are upheld. Stellantis and GM have already made plans for investment in mines as well.

Many automakers have only recently come to terms with this reality, and they are now engaged in negotiating deals directly with miners. However, this is not a surprise to Chinese EV companies; they have been using this approach for a while by attempting to gain access to lithium miners in Africa and Chile. For example, last month, CATL managed to secure a deal to purchase a nearly 25% share in CMOC for an estimated $3.7 billion.

Tesla has been showing signs of securing deals with miners in the event that the suppliers of critical raw materials fail to do so. But until then, the company is moving forward with the construction of a lithium factory on the Texas Gulf Coast, projected for completion by next year, when the construction materials come in, according to a reliable source conversant with the project.

Lithium seems to have more problems with the soaring prices, which have reached $74,500 per ton of battery-grade material in a span of two years. Its shortages are expected to get much worse by the end of the decade since the lithium sector is still developing and has no expertise to speed up production.

Dealing directly with mineral extraction companies is only one way to sidestep the shortage of needed inputs. Players in the electric vehicle space such as Nikola Corporation (NASDAQ: NKLA) will have to keep looking for innovative solutions to the other challenges they face as they ramp up their plans to address the booming demand for EVs.

Nikola Corporation (NKLA), closed Friday's trading session at $2.74, off by 4.5296%, on 9,528,954 volume. The average volume for the last 3 months is 343,046 and the stock's 52-week low/high is $2.52/$13.3196.

Compass Minerals International Inc. (CMP)

SmarTrend Newsletters, MarketBeat, The Online Investor, Daily Trade Alert, QualityStocks, Trades Of The Day, Marketbeat.com, Kiplinger Today, InvestorPlace, The Street, StreetAuthority Daily, Zacks, StreetInsider, MarketClub Analysis, All about trends, Schaeffer's, Top Pros' Top Picks, The Stock Dork, Insider Wealth Alert, Wyatt Investment Research, Daily Market Beat, CRWEFinance, BUYINS.NET, Barchart and Daily Wealth reported earlier on Compass Minerals International Inc. (CMP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Over the past year, worsening geopolitical and economic conditions have significantly increased input prices and impacted critical industries such as fertilizer. Fertilizer prices had begun surging by the end of 2021, with farmers in some areas reporting that fertilizer costs were up by more than 300% and delivery was rarely on time.

By March 2021, media outlets were reporting that fertilizer prices were at record highs due, in part, to the Russia-Ukraine war and a host of other factors. These high prices have been accompanied by a supply crunch that has pushed fertilizer costs even higher and threatened to cause a worldwide food crisis.

According to the International Fund for Agricultural Development (IFAD), the global fertilizer shortage could affect smallholder farmers the hardest. Part of the United Nations, the agency is tasked with providing support to subsistence farmers in predominantly rural areas.

IFAD president Alvaro Lario recently made this observation during the COP27 in Egypt. With the world experiencing a fertilizer shortage and a looming food crisis, IFAD has been forced to deal with the two overlapping issues amid a war in Europe that has already increased food insecurity in certain regions.

Lario said that although he was optimistic that farmers could benefit from his agency’s programing, navigating through these issues in the short term was going to be “very challenging.” He said the world is currently grappling with the critical issue of fertilizer affordability and noted that if energy prices continued trending upward, we could potentially run out of fertilizer supply.

This would significantly impact smallholder farmers and reduce their productivity even though they typically use methods such as organic farming instead of fertilizers. Many of the farmers that IFAD works with are smallholders, and they simply cannot afford the increasing prices, Lario said. He added that some farmers have been forced to sell their input and even their land to feed themselves and their families.

A deal brokered by the UN between Ukraine and Russia that would have allowed for the export of grain from Ukraine wasn’t enough to cover the supply deficit, Lario reported.

Fertilizer supplies have to be unlocked to ensure supply in the short term, and we will need to figure out how to deal with the issue next year, he said. Another deal for the exportation of Russian ammonia that would have eased the pressure on fertilizer suppliers has reportedly been held back by Western sanctions meant to harm Russia’s war effort.

Amid this crunch, entities such as Compass Minerals International Inc. (NYSE: CMP) have an opportunity to offer greater value to their shareholders as the market favors these companies.

Compass Minerals International Inc. (CMP), closed Friday's trading session at $40.56, off by 3.175%, on 343,046 volume. The average volume for the last 3 months is 358,976 and the stock's 52-week low/high is $30.67/$67.665.

Seelos Therapeutics Inc. (SEEL)

MarketBeat, StockMarketWatch, MarketClub Analysis, QualityStocks, TradersPro, Schaeffer's, BUYINS.NET, Trades Of The Day and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Thanks to a recent surge in psychedelic research, we know that psychedelic drugs can be effective at treating the symptoms of a variety of mental health conditions. Referred to as the psychedelic renaissance, this period has been characterized by increased funding for psychedelic research coupled with a surge in mainstream popularity.

More people are willing to treat conditions such as depression, eating disorders and post-traumatic stress disorder with psychedelic-assisted therapy, and these sessions have proven to be quite effective at mitigating symptoms. However, since psychedelics have been outlawed since the 1970s, most of this research is in its infancy, and the psychedelic industry as a whole is filled with people who are new to hallucinogenic drugs.

The recently established UC Berkeley Center of the Science of Psychedelics has embarked on one of the country’s first-ever programs to train and certify psychedelic guides. The nine-month program will involve 24 people drawn from several different professions including nurses, doctors, social workers, chaplains and psychologists.

Called the Certificate Program in Psychedelic Facilitation, the program covers a host of interdisciplinary issues such as contemplative science, psychotherapeutic methods, clinical science and spiritual care.

Tina Trujillo, an associate professor at the Graduate School of Education, will serve as the program’s faculty director. She said that the program participants would like to be prepared to “work safely as well as ethically” in the states where activists and voters are pushing to legalize psychedelic drugs such as psilocybin and MDMA.

Trujillo said in a recent interview with Berkeley News that the UC Berkeley Center for the Science of Psychedelics had gained FDA approval to carry out human clinical trials involving psychedelics. The center would use functional magnetic resonance imaging (fMRI) as well as psychophysics to study how psilocybin affected cognitive functioning.

Although studies have shown that psychedelics can have profound mental health benefits, Trujillo noted that this usually happens when patients are with the right facilitators and in safe conditions. One of the mitigating factors that could determine the participant’s psychedelic experience is their relationship with their facilitator, she said, adding that participants must also be properly educated on what may or may not happen during their session.

Students in the new program will learn about the history of psychedelics, neuroscience, and professional ethics among others from a team of six instructors.

According to Trujillo, the program will mostly focus on psilocybin and touch on a few other psychedelics. At the end of the program, the students will be issued a certificate in psychedelic facilitation that emphasizes psilocybin.

This training program comes at an ideal time when many psychedelics companies, such as Seelos Therapeutics Inc. (NASDAQ: SEEL), are fairly advanced in their drug-development programs. When FDA-approved treatments hit the market, there will be trained personnel to administer the psychedelic-assisted psychotherapy to patients who need these treatments.

Seelos Therapeutics Inc. (SEEL), closed Friday's trading session at $0.8159, off by 3.3408%, on 358,976 volume. The average volume for the last 3 months is 1.092M and the stock's 52-week low/high is $0.4803/$2.115.

Canaan Inc. (CAN)

MarketClub Analysis, QualityStocks, Schaeffer's, InvestorPlace, TradersPro, StreetInsider, MarketBeat, Stockhouse, AllPennyStocks, INO Market Report, BUYINS.NET, InvestorsUnderground, Stock Fortune Teller, Trades Of The Day, StockMarketWatch, StocksEarning, The Online Investor, The Street, TopStockAnalysts and SmarTrend Newsletters reported earlier on Canaan Inc. (CAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recently uncovered patent that was filed by Sony in July 2021 shows that the entertainment company has more than a casual interest in blockchain technology and non-fungible tokens (NFTs). The patent includes diagrams depicting how Sony plans to track whenever digital assets change ownership, how their visual appearance changes and how the accompanying metadata of those digital assets changes. The patent indicates that those assets could include in-game moments, characters or items within the game.

In a write-up that strongly suggests NFT-like assets, Sony’s patent lays out the specifics regarding the mechanisms that the company intends to use to monitor and keep tabs on the history of a specific item as it moves from player to player during a game. The patent claims that currently there isn’t a method to definitively distinguish a specific item that a renowned player made use of in order to win a game or tournament. The patent claims to have such a method, noting that the method will give individuals a unique opportunity to own and take pride in such a unique game or tournament-winning item. Such items hold special meaning to people, the filing asserts.

It is noteworthy that Sony PlayStation tendered this patent document in July last year when the media storm about NFTs hadn’t yet boiled over.

This patent filing isn’t PlayStation’s first interest in NFTs. During EVO 2O22, the company circulated a survey to players and fans seeking their views about any types of non-fungible tokens they may wish to buy. The answers obtained mentioned NFTs featuring esports, music artists, famous game characters and PlayStation paraphernalia as well as EVO-based NFTs.

Sony has a rewards program called PlayStation Stars. It includes digital collectibles that are handed out to qualifying recipients, but the company was quick to emphasize that those items weren’t NFTs since those cannot be sold or otherwise traded by the recipients.

It should be remembered that the video game industry has seen a lot of speculation this year regarding matters of non-fungible tokens, and several actors in this space have debuted their own products in this category. For example, GameStop unveiled its own wallet for NFTs and cryptos while EA (Electronic Arts) is actively assessing this technology. Other studios are vehemently opposed to the proliferation of NFTs in the video gaming niche, and a number of developers in this space have signed a petition denouncing or promising not to participate in creating this type of asset in the gaming field.

Regardless, Sony’s patent is further proof that blockchain technology is filtering through to all industries and sectors, and that if entities such as Canaan Inc. (NASDAQ: CAN) continue to expand their footprint, it is just a matter of time before this technology becomes commonplace.

Canaan Inc. (CAN), closed Friday's trading session at $2.76, off by 3.4965%, on 1,092,072 volume. The average volume for the last 3 months is 622,294 and the stock's 52-week low/high is $2.46/$10.50.

Global Tech Industries Group Inc. (GTII)

MarketClub Analysis, TradersPro, Schaeffer's, Wall Street Mover, StreetAuthority Daily, QualityStocks, PoliticsAndMyPortfolio, Money Morning and INO Market Report reported earlier on Global Tech Industries Group Inc. (GTII), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Global Tech Industries Group (OTCQB: GTII), a Nevada corporation, today announced that it has begun the application process to list its shares on Upstream, a trading app for digital securities and NFTs powered by Horizon Fintex and MERJ Exchange Limited. The move is designed to provide the company the opportunity to access an international, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, potentially unlocking liquidity and enhancing price discovery. “We are pursuing GTII’s listing as part of a broader effort to bring value to our shareholders and create an entire new liquidity stream for the global community,” said GTII CEO and Chairman David Reichman.

To view the full press release, visit https://ibn.fm/OgX7T

About Global Tech Industries Group Inc.

GTII is a publicly traded company incorporated in the state of Nevada, specializing in the pursuit of acquiring new and innovative technologies. For more information about the company, visit GTII-US.com.

Global Tech Industries Group Inc. (GTII), closed Friday's trading session at $3.4, off by 0.293255%, on 622,294 volume. The average volume for the last 3 months is 21,918 and the stock's 52-week low/high is $0.4302/$8.97.

The QualityStocks Company Corner

Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of gaming platforms, systems and gamingcontent, today announced its preliminary revenues for the fiscalyear ending Oct. 31, 2022, reflecting expected record revenues ofmore than $34 million. According to the update, this represents anestimated 201% improvement on revenues of $11.3 million in thecomparable twelve-month period ending Oct. 31, 2021. Golden Matrixacquired its 80% controlling interest in RKingsCompetitions Ltd(“Rkings”), which operates a business-to-consumer (“B2C”)tournament platform, at the beginning of the fiscal year. As aresult, there were no contributions by Rkings to GMGI’s overallrevenues during the prior twelve-month period. However, GoldenMatrix CEO Brian Goodman noted that “the company’s traditionalbusiness-to-business (‘B2B’) gaming segment showed a 30%improvement in revenue growth for the twelve months ended Oct. 31,2022, compared to 2021, and it currently services over 600 onlinecasino brands with more than 6.8 million registered users acrossall GM-X platforms.” To view the full press release, visit https://ibn.fm/2Em2k

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.

Technology

Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Friday's trading session at $2.4499, up 0.200409%, on 21,918 volume. The average volume for the last 3 months is 17,369 and the stock's 52-week low/high is $2.25/$10.72.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX) is developing a potential hypertension treatment with little to noside effects. “The treatment is created by processing cannabidiol(‘CBD’) using the company’s patented DehydraTECH(TM) drug deliverytechnology, which has been shown to substantially increase thebioavailability of active pharmaceutical ingredients (‘APIs’). Inhuman studies, Lexaria has shown that DehydraTECH-CBD not onlyincreases the amount of CBD in the blood by as much as 317% butalso reduces blood pressure and arterial stiffness,” a recentarticle reads. “Lexaria hopes to prove, through registered clinicaltrials, that its DehydraTECH-CBD formulation has an acceptablesafety and tolerability profile and that it is effective againsthypertension. The proof could potentially influence theregistration of DehydraTECH-CBD as the second FDA-approved CBDdrug, offering a reprieve to millions of hypertension patients whodo not have their condition under control because they receivenumerous antihypertensive drugs or are unwilling to suffer throughthese medications’ adverse side effects.” To view the full article,visit https://cnw.fm/NfZQd

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in November 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $2.2, up 2.3256%, on 17,369 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $10.72/$.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive Corp. is a Canadian developer of clean energysolutions, focusing on an on-site system for producinghydrogen-dense green ammonia

The company’s modular system can produce 300 kg per day (500 litersper day) of liquid anhydrous carbon-free ammonia — the amountneeded to fertilize a 2,000-acre farm

The system’s ability to grant end users greater energy independenceas a climate-friendly resource is filling a market need at anopportune time as industries struggle to manage supply chainchallenges created by COVID and the ongoing Russia-Ukraine war

The module is being tested in a pilot project by Canadian farmersand recently became available for pre-sale orders

Clean energy technology developer FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is proving itself as a thought leader and innovator ofclimate-friendly farming solutions vital to global economies at atime when conflicts and supply chain interruptions are stressingneeded resource markets.

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Friday's trading session at $0.1165, up 0.448353%, on 133,259 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0789/$0.201.

Recent News

GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

GeoSolar Technologies is a Colorado-based company dedicated to Net-Zero initiatives byhelping residents and businesses reduce carbon emissions andachieve energy independence. “The company’s SmartGreen(TM) Homesystems harness the power of the sun and earth to heat and coolbuildings, charge electric vehicles, and run electric applianceswhile purifying the air and maximizing energy efficiency… With aneye on global Net-Zero goals, GeoSolar’s technology empowersbuilding owners to act locally by leveraging a mix of renewableenergy sources. The company’s patent pending SmartGreen(TM) Homesystem is a total building energy ‘makeover’ that comprises solarpanels and geothermal ground loops to maintain temperature andpower household appliances and electric vehicles,” a recent articleexplains. “SmartGreen(TM) builds upon existing solutions and takesthem further with additional measures that include tightening thebuilding envelope and upgrading insulation, windows and lightingsystems. With options to build systems into new construction orexisting buildings, SmartGreen(TM) helps property owners cut CO2emissions by up to 8 tons per year while reducing or eveneliminating energy bills.” To view the full article, visit https://ibn.fm/bxSiX

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.

 

The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.

GeoSolarPlus®

The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

  • Making a real planet-changing difference in reducing air pollution
  • Eliminating or significantly reducing homeowners’ future utility bills
  • Enjoying lifetime energy independence and protection from price escalation and energy shortages
  • Eliminating greenhouse gas emissions from operation of home and daily life
  • Increasing home value
  • An integrated design for seamless operation of renewable energy systems
  • Maintaining a significantly healthier living environment
  • Leveraging existing renewable energy tax credits and electrification incentives
  • Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.


Recent News

chart

QSAM Biosciences Inc. (OTCQB: QSAM)

The QualityStocks Daily Newsletter would like to spotlight QSAM Biosciences Inc. (OTCQB: QSAM).

Even though we have come a long way from the days of slavery,racial discrimination and disparities are still entrenched in American society. In many cases, racial biases prevent peopleof color from receiving high-quality medical care, with somestudies showing that Black Americans are often undertreated for pain.Overall, the National Academy of Medicine has found that Blackpatients are much more likely to receive inferior care from their physicians compared to White patients. When it comes toserious medical conditions such as cancer, these disparities canhave lifelong and even fatal consequences. Speaking at the annualPatient-Centered Oncology Care (PCOC) meeting, the NationalComprehensive Cancer Network (NCCN) senior director of policy &advocacy Alyssa Schatz said that adhering to clinical guidelinescould go a long way toward mitigating treatment disparities incancer patients. As these disparities are addressed, all cancerpatients will have an equal chance of benefiting from the superioroncology formulations that entities such as QSAM Biosciences Inc. (OTCQB: QSAM) are focused on bringing to market.

QSAM Biosciences Inc. (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients.

QSAM Biosciences was founded in 2020 by Executive Chairman Dr. C. Richard Piazza and CEO Douglas Baum. It is headquartered in Austin, Texas.

CycloSam®

CycloSam®, QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. By leveraging a patented, low specific activity form of Samarium-153 (resulting in far less undesirable europium impurity) and what management believes to be a superior chelating agent in DOTMP, CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the bone tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters are currently being tested in an FDA-cleared clinical trial.

CycloSam® has been shown in laboratory testing to cause significantly less (30x less) buildup of long-lived radionuclidic impurities than prior FDA-approved drugs, which management believes will enable the ability to safely administer therapeutic doses via higher and multiple-dose regimens and effectively expand its potential clinical utility to therapeutic uses in areas of high unmet medical needs.

The indications for CycloSam® currently being evaluated by QSAM Biosciences include:

  • Metastatic Bone Cancers – On April 28, 2022, QSAM Biosciences announced that the first patient had commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. As noted in the release, the study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam®.
  • Pediatric Osteosarcoma/Ewing’s Sarcoma – On February 2, 2022, the company announced that the U.S. FDA has granted Rare Pediatric Disease Designation to CycloSam for the treatment of osteosarcoma. Combined with a previously granted orphan drug designation for osteosarcoma received in 2021, this milestone “may allow QSAM to potentially bring CycloSam® to market more rapidly through additional incentives and eligibilities,” according to CEO Douglas Baum.
  • Bone Marrow Ablation – In a 2020 single patient Investigational New Drug (IND) study, an investigator concluded that high-dose CycloSam® can be administered safely to ablate bone marrow in advance of a stem cell transplant with no apparent renal toxicity and no unexpected adverse events attributable to the drug.

QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio. The company has secured 14 patents across three distinct patent families spanning the U.S., Japan, Canada and the European Union.

Market Outlook

Through its ongoing development of CycloSam®, QSAM Biosciences is targeting multiple large and underserved market opportunities. According to the American Cancer Society, roughly 400,000 new cases of malignant bone metastasis are diagnosed annually in the U.S. alone. Additionally, QSAM will pursue indications for osteosarcoma and Ewing’s sarcoma that are the most common primary malignancies of bone tissues in children.

Despite this pressing need, the current standard of care for bone cancer is aggressive and suboptimal, leading to marginal success with significant side effects and poor long-term survival prognosis. As a result, QSAM Biosciences estimates a sizable market opportunity for its development pipeline.

  • Bone Metastasis has an estimated total addressable market of $20 billion in the U.S. based on total new cases and comparable drug pricing.
  • Osteosarcoma/Ewing’s Sarcoma have a total addressable market of roughly $125 million in the U.S. based on approximately 1,000 new cases in 2021.
  • The total addressable market for Bone Marrow Ablation is projected at $1 billion, with an estimated 32,000 procedures completed annually.

The company anticipates that the ability to administer CycloSam® for higher and multiple-dose regimens may expand its clinical utility for therapeutic uses in additional areas of high unmet medical needs.

Management Team

QSAM Biosciences is led by an experienced management team and board with an extensive record of FDA approvals, big pharma partnerships and M&A transactions.

Dr. C. Richard Piazza is the Executive Chairman of QSAM Biosciences. Since 2017, he has also served as President and CEO of IGL Pharma Inc., the licensor of CycloSam®, and as a consultant to IsoTherapeutics Group LLC, the inventors of the technology. Dr. Piazza also currently serves on the board of directors of NovaScan LLC, a privately held cancer detection and diagnostics company. He has more than 48 years of health care experience in both medical devices and pharmaceutical/biotech and has led several technology companies to market success, including numerous FDA approvals in both sectors. Dr. Piazza obtained a BS in Economics and a BS in Speech Pathology from the State University of New York and an MA & PhD in Economics from the University of Buffalo and Leeds University.

Douglas R. Baum is the company’s CEO and Director. He brings to QSAM Biosciences over 30 years of experience in the bioscience and biotech industries, including development, FDA/EMA approval and commercialization of multiple drugs and medical devices. Mr. Baum has overseen 15 product approvals through the FDA and EMA and raised over $85 million in capital to fund breakthrough technologies. From 2017 to 2020, he consulted with multiple medical schools and biotech and pharmaceutical companies, and, from 2012 to 2017, he served as President, Chief Executive Officer and Director of Xeris Pharmaceuticals Inc. Mr. Baum holds a Master of Science in Technology Commercialization and a BBA in International Business and Marketing from the University of Texas.

Adam King is the CFO of QSAM Biosciences. He is also the Founder and CEO of King Consulting Group, where he provides a range of financial and reporting services for clients. Before founding King Consulting Group in January 2021, Mr. King was the CFO for Netsertive, a venture-backed digital marketing company. From 2016 to 2018, he was the Office Managing Audit Director for BDO’s Greenville, South Carolina, office, in addition to serving as Audit Director in Raleigh, North Carolina, and Boston, Massachusetts. While at BDO, Mr. King worked with various clients, from tech and life science start-ups to billion-dollar publicly traded companies. He holds a Bachelor of Science in Accounting from Elon University and is a CPA in Raleigh, North Carolina.

QSAM Biosciences Inc. (OTCQB: QSAM), closed Friday's trading session at $5.4, even for the day, on 200 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.50/$14.00.

Recent News

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

While governmental leaders continue to work toward measurableclimate progress, U.S.-based Correlate Infrastructure Partners Inc.is helping corporate clients attain ESG successes sought byinvestors 

The company recently reported that completion of constructionmilestones in contracted projects has netted it an 877 percent jumpin revenues from Q2 to Q3, amounting to a 15,024 percent increaseYOY

CIPI’s efforts include helping clients achieve significant yetaffordable change in their facilities’ utilities usage throughimprovements to mechanical, electrical, and plumbing processes, theaddition of solar upgrades, water optimization, and other strategicmeasures

Nearly a decade has passed since world leaders agreed to pursuepollution reduction strategies to keep global temperature increasesfrom peaking at more than 1.5 degrees Celsius above the planet-widetemperature peaks recorded nearly 300 years ago, and many climatepolicy makers who gathered this month for the latest UnitedNations-sponsored Conference of the Parties (“COP27”) climatechange conference expressed concerns that not enough has been doneto adhere to the agreement (https://ibn.fm/q0HDx).While U.S. President Joe Biden and Chinese President Xi Jinpingdeclared Nov. 14 they would set aside disagreements over some ofthe countries’ policies enough to work together on fighting climatechange, protecting global health and safeguarding access to food,many industries are also doing their part to show environmental,social and governance (“ESG”) responsibility in order to appeal toinvestors (https://ibn.fm/MK8lv).Correlate Infrastructure Partners (OTCQB: CIPI), a U.S. company that advises the commercial real estate industry(companies that develop and rent out commercial buildingproperties) on potential ESG improvements and financingopportunities to make those improvements both workable andeconomical, is demonstrating its own success through a major jumpin revenues from its operations.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.

Subsidiaries

Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Friday's trading session at $1.4, even for the day, on 550 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.32/$3.25.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

The presentation focused on BiondVax’s yeast fermentation system tomanufacture innovative alpaca-derived recombinant nanosizedVHH-antibodies (NanoAbs) and highlighted the company’s NanoAbs as aplatform for development of therapeutics addressing diseases withlarge unmet medical needs and attractive commercial opportunities

BiondVax’s lead NanoAb candidate, an inhaled COVID-19 treatment,exhibits significant competitive advantages over currentlyavailable mAbs and oral COVID-19 therapies

Development of additional NanoAbs, targeting psoriasis, asthma,psoriatic arthritis and wet macular degeneration is underway via astrategic collaboration with the Max Planck Institute forMultidisciplinary Sciences and the University Medical CenterGottingen (“UMG”), both in Germany

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, andcommercializing innovative immunotherapeutic products primarily forthe treatment of infectious diseases and autoimmune diseases,recently presented at Recent Advances in Fermentation Technology(“RAFT”) 14, a conference of the Society for IndustrialMicrobiology and Biotechnology (“SIMB”), which took place inOrlando, Florida. RAFT provides a platform for academic andindustrial scientists to discuss the latest developments infermentation technology. BiondVax’s Head of Technical R&D, Dr. Dalit Weinstein Fischer, presented the company’s Nano-sized solution for a massivechallenge: NanoAbs as a platform for COVID-19, asthma, andpsoriasis therapies at the Caribe Royale Orlando on November 8,2022 (https://ibn.fm/ziT4B).

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Friday's trading session at $0.87, even for the day, on 36,594 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.5335/$3.49.

Recent News

REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

REZYFi, a growth mortgage origination and specialized financing companyservicing the needs of both traditional and non-traditionalconsumers and businesses, is uniquely positioned as the firstcannabis mortgage banker in the United States. “REZYFi operatesthrough two wholly owned subsidiaries – REZYFi Lending and ResMac,Inc. REZYFi Lending leverages a wide network to offer options suchas 15- to 30-year fixed-rate, FHA, VA, and jumbo loans and reverseand adjustable-rate mortgages. The company expects increasedfunding in marketing and loan agents to drive significantorigination growth over the next two years, further supported bythe company’s launch of a high-margin cannabis division,” a recentarticle reads. “ResMac has been in operation for 13 years, havingclosed more than 20,000 loans for more than 15,000 clients. ThroughResMac, REZYFi operates as a direct lender and originator ofresidential mortgages, with active mortgage correspondent andmortgage operations. Through its correspondent segment, ResMacprimarily purchases and aggregates residential mortgages fromtrusted third-party originators… Through its unique offering,REZYFi is leading the industry with a diversified approach to thereal estate lending sector, positioning itself to capitalize ongrowth in multiple verticals in years to come.” To view the fullarticle, visit https://ibn.fm/OnAgc.As marijuana legalization spreads across the United States, manycompanies have worked to address the industry-specific challengesthat operators faced, particularly with regard to access tofinancial services, insurance, legal, compliance and regulatoryissues as well as the security challenges created by the cash-onlyoperations of many marijuana companies. There is speculation andhope that the SAFE Banking Act, or another version of this law, could be passed in this coming lame duck session of Congress. Howwill such a law impact the companies that stepped in to servecannabis businesses? Some in the industry, including TylerBeurlein, who works as a business development officer atColorado-based SHF Holdings, think it will take years for any banking reform to seep through to the practical realitiesof the marijuana industry. Given that marijuana would still remainfederally illegal, not many traditional banks will enter theindustry, he says, and that would leave existing players with spaceto serve the clients they have always served. What is certain isthat the passage of a cannabis banking law would have far-reachingramifications, and individual companies such as REZYFi Inc. would have to assess how to adjust their strategies in light ofthe particulars of the banking law when it is implemented.

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.

Operations

REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.


Recent News

chart

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development andmanufacturing of rare cannabinoids and cannabinoid analogs, hasentered into a securities purchase agreement with twohealthcare-focused institutional investors. The agreement outlinesplans for the issuance and sale of 1,818,185 of INM common shares;the shares will be issued at a purchase price of $3.30 per share orprefunded warrant. In addition, the agreement notes that INM willissue unregistered preferred investment options to the sameinvestors; those options include purchasing up to 3,272,733additional common shares. According to the announcement, thecompany anticipates the private placement, which is expected toclose on or about Nov. 21, 2022, could total approximately $6million in gross proceeds. INM plans to use the funds to supportthe development of its pharmaceutical drug candidate as well asadvance manufacturing know-how of cannabinoids and cannabinoidanalogs and strengthen intellectual property development; thefunding may also be used to assist with other commercial activitiesand general working capital purposes. H.C. Wainwright & Co. isthe exclusive placement agent for the offering. To view the fullpress release, visit https://ibn.fm/SA7Zi

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Friday's trading session at $2.76, off by 28.125%, on 892,813 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.40/$54.50.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

The past two decades have seen dozens of American states legalize cannabis for medical and recreational purposes. Cannabis has since provento be one of the fastest-growing industries in the country, generating billions of dollars in salesand creating hundreds of thousands of new employment opportunities. However, even though the UnitedStates is now home to thousands of legal cannabis businesses, the illicit marijuana market still thrives. Data shows that in 2019 black market sellers sold around $8.7 billion worth of cannabis in California, the country’s largest marijuana market compared to$3.1 billion worth of legal sales. Illegal cannabis cultivation hasalso significantly contributed to water depletion, pesticide andchemical contamination, and endangered ecosystems.Anacostia Organics CEO Linda Mercado Greene says that she hasbecome concerned with the number of unregulated businesses that donot strive to meet safety and testing requirements. Consequently, it is incredibly important that consumers areeducated on the importance of purchasing legal, safe and regulatedproducts from numerous licensed entities, such as Flora Growth Corp. (NASDAQ: FLGC), which operate in different markets around the country.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Friday's trading session at $0.4, off by 11.3279%, on 1,034,757 volume. The average volume for the last 3 months is 1.035M and the stock's 52-week low/high is $0.40/$4.21.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services (OTCQB: SHRG), a company dedicated to maximizing shareholder value, is guided byclear vision, mission and values in its commitment to promotehealth, wealth and happiness by reshaping how entrepreneurs succeedtoday. “The company notes that ‘the quality of internal decisionsdetermines the quality and success of outcomes. Emotional decisionmaking can often tilt the decision-making objectives. Adherence toguiding principles and values serve all in arriving at the mosteffective and collaborative decision.’ The company states itsguiding principles and values as follows: we exist to serve people;technology must always be a strength; less is more; research is thefoundation to excellence in decision-making; quality is thefoundation to sustainable success; speed is important; and nocompromise,” reads a recent article, which contains excerpts fromthe company’s website. “Sharing Services doesn’t just talk the talkof values and principles; the company is adamant about transformingthese statements into real-world and real-life action as it worksto capture profitable market share through acquisition, newbusiness entry, and management of diverse business models. TheSharing Services combined platform leverages the capabilities andexpertise of various companies that market and sell products directto the consumer.” To view the full article, visit https://ibn.fm/IDxmF

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed the day's trading session at $1.01, up 23.17%, on 276,351 volume with 217 trades. The average volume for the last 3 months is 279,074 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

 

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.

 

Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.

Enclave

Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Friday's trading session at $0.14, even for the day. The average volume for the last 3 months is 20,000 and the stock's 52-week low/high is $0.06/$0.18.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.